REG - Hikma Pharmaceutical - Annual Information Update <Origin Href="QuoteRef">HIK.L</Origin>

Hikma PharmaceuticalsAnnouncement

09/04/2015 11:20

RNS Number : 7302J
Hikma Pharmaceuticals Plc
09 April 2015
Hikma Pharmaceuticals PLC
Annual Information Update
London, 9 April 2015. In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. In accordance with Prospectus Rule 5.2.7, it is acknowledged that whilst the information referred to in this update was up to date at the time of publication, such disclosures may, at any time, become out of date due to changing circumstances.
Stock Exchange Announcements
Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:
Date 
Headline 
09/04/2015
Annual Financial Report
01/04/2015
Hikma Prices debut $500 million five-year eurobond
31/03/2015
Stabilisation Notice
19/03/2015
Fixed income investor meetings
13/03/2015
Director/PDMR Shareholding
11/03/2015
Holding(s) in Company
11/03/2015
Final Results
23/01/2015
Director Declaration
21/01/2015
Notification of major interest in shares
15/01/2015
Blocklisting Interim Review
12/01/2015
Hikma to launch colchicine 0.6mg capsules
07/01/2015
Total Voting Rights
12/11/2014
Director/PDMR Shareholding
11/11/2014
Total Voting Rights
07/11/2014
Notification of major interest in shares
06/11/2014
Directorate Change
06/11/2014
Interim Management Statement
24/10/2014
Hikma announces receipt of Warning Letter from FDA
20/10/2014
Director/PDMR Shareholding
10/10/2014
Statement re Colchicine
10/10/2014
Director/PDMR Shareholding
06/10/2014
Blocklisting Interim Review
06/10/2014
Total Voting Rights
30/09/2014
Regulatory Approval Colchicine
17/09/2014
Acquisition
20/08/2014
Dividend Declaration
20/08/2014
Interim Results
07/08/2014
Notice of Interim Results Announcement
28/07/2014
Director/PDMR Shareholding
24/07/2014
Acquisition
15/07/2014
Acquisition
14/07/2014
Total Voting Rights
27/06/2014
Director/PDMR Shareholding
23/06/2014
Director/PDMR Shareholding
11/06/2014
Director/PDMR Shareholding
10/06/2014
Total Voting Rights
29/05/2014
Director/PDMR Shareholding
29/05/2014
Director/PDMR Shareholding
28/05/2014
Acquisition
27/05/2014
Director/PDMR Shareholding
15/05/2014
Results of AGM
15/04/2014
Interim Management Statement
06/05/2014
Director/PDMR Shareholding
17/04/2014
Annual Information Update
All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system. These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com). 
Documents filed with the Financial Services Authority
The Company has filed the following documents with the Financial Services Authority ("FSA") visa the National Storage Mechanism over the previous 12 months. These documents are available at http://www.hemscott.com/nsm.door at the Company's registered office.
Date
Document
09/04/2015
Annual Report and Accounts 2014
09/04/2015
Notice of 2015 Annual General Meeting 
09/04/2015
Proxy forms for the 2015 Annual General Meeting
10/04/2014
Annual Report and Accounts 2013
10/04/2014
Notice of 2014 Annual General Meeting 
10/04/2014
Proxy forms for the 2014 Annual General Meeting
Documents filed with Companies House
The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below. 
Date Filed
Form
Description
07/04/2015
SH01
Statement of Capital GBP 19,887,933.90
12/12/2014
AP01
Director Appointed Dr. Pamela Josephine Kirby
11/11/2014
SH01
Statement of Capital GBP 19,862,523.90
06/10/2014
SH01
Statement of Capital GBP 19,855,195
08/09/2014
AR01
No Member List
10/06/2014
SH01
Statement of Capital GBP 19,843,04.77
09/06/2014
RES01
Alter Articles 15/05/2014
09/06/2014
MEM/ARTS
Articles of Association
21/05/2014
SH04
Treasury Capital GBP 0
20/05/2014
RES01
Alter Articles 15/05/2014
20/05/2014
AA
Group of Companies' Accounts made up to 31/12/13
15/05/2014
AP01
Director Appointed Mr. Patrick Noel Butler
15/05/2014
TM01
Appointment Terminated, Director Samih Darwazah
15/05/2014
TM01
Appointment Terminated, Director David Rowe Ham
23/04/2014
MR01
Registration of a Charge/ Charge Code 055579340003
07/04/2014
SH01
Statement of Capital GBP 19,815,699.70
Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House "Webcheck" at www.companieshouse.gov.uk. 
Documents provided to Shareholders
Further Information
Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW. 
Peter Speirs
Company Secretary
9 April 2015
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Peter Speirs
Company Secretary
+44 20 7399 2670
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $299 million. 

This information is provided by RNS
The company news service from the London Stock Exchange
  END
AIUBKLFBEZFFBBZ